Literature DB >> 33748038

Impact of Pediatric Obesity on Diurnal Blood Pressure Assessment and Cardiovascular Risk Markers.

Margaret O Murphy1, Hong Huang2, John A Bauer2, Aric Schadler2, Majd Makhoul3, Jody L Clasey4, Aftab S Chishti1, Stefan G Kiessling1.   

Abstract

Background: The prevalence of hypertension is increasing particularly among obese children and adolescents. Obese children and adolescents with hypertension are likely to remain hypertensive as they reach adulthood and hypertension is linked to an increased risk for cardiovascular disease. Twenty-four-hour ambulatory blood pressure monitoring (ABPM) has become one of the most important tools in diagnosing hypertension in children and adolescents and circadian patterns of blood pressure may be important disease-risk predictors.
Methods: A retrospective chart review was conducted in patients aged 6-21 years who underwent 24-h ABPM at Kentucky Children's Hospital (KCH) from August 2012 through June 2017. Exclusion criteria included conditions that could affect blood pressure including chronic kidney disease and other renal abnormalities, congenital heart disease, cancer, and thyroid disease. Subjects were categorized by body mass index into normal (below 85th percentile), overweight (85th-95th percentile), stage I obesity (95th-119th percentile), stage II obesity (120th-139th) and stage III obesity (>140th). Non-dipping was defined as a nocturnal BP reduction of <10%.
Results: Two hundred and sixty-three patients (156 male patients) were included in the analysis, of whom 70 were normal weight, 33 overweight, 55 stage I obesity, 53 stage II, and 52 stage III obesity. Although there was no significant difference between normal weight and obese groups for prevalence of hypertension, there was a greater prevalence of SBP non-dipping in obese patients as BMI increased (p = 0.008). Furthermore, non-dippers had a significantly elevated LVMI as well as abnormal lab values for uric acid, blood lipid panel, creatinine, and TSH (p < 0.05). Conclusions: These findings demonstrate that obese children and adolescents constitute a large proportion of hypertensive children and adolescents and the severity of pediatric obesity is associated with nocturnal BP non-dipping. Additionally, obesity in children is linked to several cardiovascular risk factors including left ventricular hypertrophy, dyslipidemia, and elevated uric acid levels. Further studies utilizing ABPM measures on risk stratification in this very high-risk population are warranted.
Copyright © 2021 Murphy, Huang, Bauer, Schadler, Makhoul, Clasey, Chishti and Kiessling.

Entities:  

Keywords:  blood pressure; cardiovascular risk; left ventricular hypertrophy; nocturnal dipping; obesity; pediatric

Year:  2021        PMID: 33748038      PMCID: PMC7969716          DOI: 10.3389/fped.2021.596142

Source DB:  PubMed          Journal:  Front Pediatr        ISSN: 2296-2360            Impact factor:   3.418


  49 in total

1.  The Association of Pediatric Obesity With Nocturnal Non-Dipping on 24-Hour Ambulatory Blood Pressure Monitoring.

Authors:  Ian R Macumber; Noel S Weiss; Susan M Halbach; Coral D Hanevold; Joseph T Flynn
Journal:  Am J Hypertens       Date:  2015-08-26       Impact factor: 2.689

2.  Ambulatory blood pressure monitoring in children with obstructive sleep apnea and primary snoring.

Authors:  Silke Anna Theresa Weber; Victor José Barbosa dos Santos; Graziela de Oliveira Semenzati; Luis Cuadrado Martin
Journal:  Int J Pediatr Otorhinolaryngol       Date:  2012-03-18       Impact factor: 1.675

3.  Relationship of ambulatory blood pressure and body mass index to left ventricular mass index in pediatric patients with casual hypertension.

Authors:  Prema Ramaswamy; Sathish Chikkabyrappa; Keyur Donda; Marina Osmolovsky; Mary Rojas; Daniela Rafii
Journal:  J Am Soc Hypertens       Date:  2015-11-22

4.  BP control and left ventricular hypertrophy regression in children with CKD.

Authors:  Juan C Kupferman; Lisa Aronson Friedman; Christopher Cox; Joseph Flynn; Susan Furth; Bradley Warady; Mark Mitsnefes
Journal:  J Am Soc Nephrol       Date:  2013-09-26       Impact factor: 10.121

5.  Childhood obesity: are we all speaking the same language?

Authors:  Katherine M Flegal; Cynthia L Ogden
Journal:  Adv Nutr       Date:  2011-03-10       Impact factor: 8.701

6.  Relationship between ambulatory blood pressure and follow-up clinic blood pressure in elderly patients with systolic hypertension.

Authors:  Robert H Fagard; Jan A Staessen; Lutgarde Thijs; Christopher J Bulpitt; Denis Clement; Peter W de Leeuw; Matti Jääskivi; Giuseppe Mancia; Eoin O'Brien; Paolo Palatini; Jaakko Tuomilehto; John Webster
Journal:  J Hypertens       Date:  2004-01       Impact factor: 4.844

7.  Effects of obesity and race on left ventricular geometry in hypertensive children.

Authors:  Cozumel S Pruette; Barbara A Fivush; Joseph T Flynn; Tammy M Brady
Journal:  Pediatr Nephrol       Date:  2013-05-24       Impact factor: 3.714

8.  Global Prevalence of Hypertension in Children: A Systematic Review and Meta-analysis.

Authors:  Peige Song; Yan Zhang; Jinyue Yu; Mingming Zha; Yajie Zhu; Kazem Rahimi; Igor Rudan
Journal:  JAMA Pediatr       Date:  2019-12-01       Impact factor: 16.193

9.  Serum cardiovascular risk biomarkers in pre-pubertal obese children.

Authors:  Albane B R Maggio; Nathalie J Farpour-Lambert; Yacine Aggoun; Katia Galan; Fabrizio Montecucco; François Mach; Maurice Beghetti
Journal:  Eur J Clin Invest       Date:  2018-08-06       Impact factor: 4.686

Review 10.  Childhood obesity and adult cardiovascular disease risk factors: a systematic review with meta-analysis.

Authors:  Amna Umer; George A Kelley; Lesley E Cottrell; Peter Giacobbi; Kim E Innes; Christa L Lilly
Journal:  BMC Public Health       Date:  2017-08-29       Impact factor: 3.295

View more
  1 in total

1.  Creatinine-based GFR-estimating equations in children with overweight and obesity.

Authors:  Mark J C M van Dam; Hans Pottel; Anita C E Vreugdenhil
Journal:  Pediatr Nephrol       Date:  2022-02-24       Impact factor: 3.651

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.